Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

Further Publications

Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis

Lancet Oncol

Jin F, Vajdic CM, Poynten IM, McGee-Avila JK, Castle PE, Grulich AE

doi: 10.1016/S1470-2045(24)00189-X

Further Publications

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

Lancet Oncol

Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, Guzman-Becerra N, Joshi M, Mehta A, Navarro WH, Nikiforow S, O'Reilly RJ, Reshef R, Ruiz F, Spindler T, Prockop S

doi: 10.1016/S1470-2045(23)00649-6

Lung, Respiratory and Thoracic Cancer

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

Cancer Cell

Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, Gayevskiy V, Elhossiny AM, Srivastava MK, Patil NS, Smith KA, Jesudason R, Chan C, Chang PS, Fernandez M, Rost S, McGinnis LM, Koeppen H, Gay CM, Minna JD, Heymach JV, Chan JM, Rudin CM, Byers LA, Liu SV, Reck M, Shames DS

doi: 10.1016/j.ccell.2024.01.010

Further Publications

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease

Eur J Cancer

Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N, Pundole X, Aldrich JD, Carey P, Khan M, Geng Y, Pratt G, Suarez-Almazor ME

doi: 10.1016/j.ejca.2024.114148

Lung, Respiratory and Thoracic Cancer

Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort

Lung Cancer

Li Y, Wong M, Zhan L, Corke L, Brown MC, Cheng S, Khan K, Balatnaram K, Chowdhury M, Sabouhanian A, Herman J, Walia P, Strom E, Patel D, García-Pardo M, Schmid S, Eng L, Sacher AG, Leighl N, Bradbury PA, Shepherd FA, Shultz D, Liu G

doi: 10.1016/j.lungcan.2024.107823

Gastrointestinal Cancer

Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients

Eur J Cancer

Barbe R, Belkouchi Y, Menu Y, Cohen R, David C, Kind M, Harguem S, Dawi L, Hadchiti J, Selhane F, Billet N, Ammari S, Bertin A, Lawrance L, Cervantes B, Hollebecque A, Balleyguier C, Cournede PH, Talbot H, Lassau N, Andre T

doi: 10.1016/j.ejca.2024.114020

Lung, Respiratory and Thoracic Cancer

Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade

Clin Cancer Res

Rosner S, Connor S, Sanber K, Zahurak M, Zhang T, Gurumurthy I, Zeng Z, Presson B, Singh D, Rayes R, Sivapalan L, Pereira G, Ji Z, Thummalapalli R, Reuss JE, Broderick SR, Jones DR, Deutsch JS, Cottrell TR, Chaft J, Spicer J, Taube J, Anagnostou V, Brahmer JR, Pardoll DM, Ji H, Forde PM, Marrone KA, Smith KN

doi: 10.1158/1078-0432.CCR-24-2983

Lung, Respiratory and Thoracic Cancer

Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates

Clin Cancer Res

Dall'Olio FG, Zrafi W, Roelants V, Ambrosini V, Fourquet A, Mitea C, Passiglia F, Bauckneht M, Bonardel G, Conci N, Benitez JC, Arena V, Namour C, Naigeon M, Monnet I, Beshiri K, Hoton D, Dursun S, Danlos FX, Argalia G, Aldea M, Rovera G, Derosa L, Iebba V, Gietema HA, Gounant V, Lacroix V, Remon J, Gautheret D, Chaput N, Job B, Kannouche PL, Velasco-Nuño M, Zitvogel L, Cella E, Chícharo de Freitas JR, Vasseur D, Bettaieb MA, Tagliamento M, Hendriks L, Italiano A, Planchard D, Marabelle A, Barlesi F, Novello S, De Andreis D, Aboubakar Nan F, Ardizzoni A, Zalcman G, Garcia C, Besse B

doi: 10.1158/1078-0432.CCR-24-1993

Lung, Respiratory and Thoracic Cancer

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Eur J Cancer

Saalfeld FC, Möller J, Christopoulos P, Wenzel C, Rasokat A, Wang XA, Vathiotis I, König D, Illini O, Grohé C, Wiesweg M, Wesseler C, Schubart C, Pelusi N, Rohde G, Overbeck TR, Kirfel J, Alt J, Kauffmann-Guerrero D, Griesinger F, Kulhavy J, Allgäuer M, Klimova A, Schütz M, Aust DE, Hochmair MJ, Rothschild SI, Syrigos KN, Veluswamy R, Michels S, Stenzinger A, Jöhrens K, Wermke M

doi: 10.1016/j.ejca.2024.115065

Related content

Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease

Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort

Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients

Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade

Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy